Evidence map›Paper›PMID 37265183›Full record

ArticleTumori2023

Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib.

Martina Dameri, Alessandro Garlaschi, Paola Cuccarolo, Andrea Ceccardi, Mario Stabile, Irene Valente, Licia Gristina, Massimo Calabrese, Alberto Ballestrero, Alberto Tagliafico and 1 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Tumori, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Martina DameriDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Alessandro GarlaschiDepartment of Radiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Paola CuccaroloDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Andrea CeccardiDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Mario StabileDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Irene ValenteDepartment of Radiology, Asl4, Lavagna, Italy.
Licia GristinaDepartment of Radiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Massimo CalabreseDepartment of Radiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Alberto BallestreroDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Alberto TagliaficoDepartment of Radiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Gabriele ZoppoliDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.ORCID 0000-0002-1619-1708
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITAzienda Unità Sanitaria Locale Della Romagna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up. This is the first case report describing such clinical outcome in breast cancer following Ixazomib, bendamustine and dexamethasone combination therapy. To investigate the potential antitumoral activity of Ixazomib in breast cancer, we performed

Indexed as

Breast NeoplasmsMultiple MyelomaAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBoron CompoundsDexamethasoneFemaleGlycineHumansNeoplasm Recurrence, LocalRecurrenceBendamustine HydrochlorideBoron CompoundsDexamethasoneGlycineixazomibbreast cancerixazomibMCF7Multiple myelomaT47D

Identifiers

PMID37265183
PMCPMC10702304
OpenAlexW4379095380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.